Tag: Syngene International
Overstepping the mark
The requirement to submit a test licence in the drugs and cosmetics rules goes beyond the ambit of the Parent Act, and is a hindrance to R&D for pharma companies, writes Syngene International's Shreekanth Katti
LATEST ON LAW.ASIA
MOST READ ON LAW.ASIA
Playing catch-up
Shared venture documentation gaps slow India funding rounds and shape foreign capital perceptions of ecosystem maturity
